Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: old 'n cranky who wrote (12548)	12/15/2019 9:38:01 PM
From: RoadyHD	Read Replies (1) \| Respond to of 12873

COGS is not defined strictly by GAAP and so has gray areas for disagreement. But a strict definition would be defined in the licensing agreement and be clear on what's included and what is not, greatly reducing the gray to immateriality. Licensing agreements can be very detailed on definitions of sales, net sales, net profits, gross profits, etc.

To: old 'n cranky who wrote (12548)	12/19/2019 4:42:34 PM
From: HardToFind	Read Replies (1) \| Respond to of 12873

10% gross profit royalty (net sales less COGS and less amortized development costs that were paid to TheraCour) Do real companies really do that? Generally, real companies do a percentage of (net) revenues, because it is hard to fudge and relatively easy to verify. Which is, BTW, what TheraCour does (not claiming it is a real company), notwithstanding Diwan's bogus protests to the contrary. Read any document describing the deal. It will clearly state *Net Revenues*, nothing else deducted.